Oral drug LM11A-31 preserves brain networks in Alzheimer's trial
An experimental drug has shown it can slow the breakdown of brain communication networks in Alzheimer's patients, signaling a potential shift in the longevity medicine market away from simply clearing amyloid plaques.
Data presented at the Alzheimer’s Association International Conference in London showed that the drug LM11A-31 significantly slowed the decline of brain functional-network connectivity compared to a placebo. The Phase 2a trial analysis, involving 159 participants with mild-to-moderate Alzheimer’s, found the strongest effects at a 400 mg dose. It tested a mechanism entirely different from the plaque-clearing antibodies currently dominating the market.
For the European pharmaceutical and longevity sectors, the findings represent a potential inflection point. The current generation of FDA-approved Alzheimer's drugs acts as a cleanup crew, targeting sticky amyloid protein deposits. LM11A-31, developed by clinical-stage biotech PharmatrophiX, takes a different approach by reinforcing the brain's internal wiring before it breaks down. For investors, this signals a diversification of the clinical pipeline away from a single biological target.
Researchers from Indiana University School of Medicine and PharmatrophiX used novel metabolic network maps to measure how effectively different parts of the brain cooperated, rather than just looking at regional shrinkage. “LM11A-31 is designed to protect the synapses – the connections between neurons – that enable the brain to function as an integrated network. What makes these findings particularly important is that advances in brain imaging and network analysis now allow us to measure the activity of those networks directly in living patients,” said Dr Frank M Longo, co-founder of PharmatrophiX.
The imaging results build on earlier Phase 2a data from 242 participants, which showed approximately a 50% reduction in cognitive decline and a favorable safety profile. “These findings, together with our Phase 2a biomarker results, provide encouraging evidence that LM11A-31 may help preserve the brain networks supporting cognition and strongly support the rigorous clinical development of this program for people living with Alzheimer’s disease,” said David Setboun, CEO of PharmatrophiX. The company is now planning a larger Phase 2b/3 trial.
The data also revealed that men and women exhibited different patterns of brain-network decline and responded differently to the treatment. For the longevity economy, where personalized medicine is a major investment theme, this complicates drug development but increases the potential market for highly targeted interventions. Future brain-aging therapies may need to be developed and prescribed differently depending on biological sex.
“By measuring how these networks perform in terms of efficiency, and how these quantitative measures change with time and by sex, we can gain a deeper understanding of the biological effects of a therapy and obtain measures of brain function that are as closely related to cognition as currently possible,” said Dr Paul R Territo, Professor of Medicine at Indiana University. As Europe's population ages, preserving cognitive function rather than just clearing biological waste could redefine how healthcare systems and investors approach the economics of longevity.
